… II study was to estimate the tumor response rate and safety profile of erlotinib HCl (erlotinib, …
Thirty-four patients received 150 mg erlotinib orally once daily for up to 48 weeks or until …

… Another multicenter, randomized, controlled phase III trial has completed enrollment of …
/day of erlotinib in combination with gemcitabine and cisplatin (44, 45). A phase Ib trial has been …

… The purpose of this study was to define the maximum tolerated dose of erlotinib and …
glioma received erlotinib alone or combined with temozolomide in this dose-escalation study. In …

… In preclinical studies, erlotinib has substantial antitumor activity … Phase I data showed that
erlotinib was well tolerated, with … Phase III trials with erlotinib in non-small cell lung cancer …

… TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin
and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:…

… was the first and largest trial to our knowledge to prospectively investigate erlotinib versus …
patients in the OPTIMAL trial. These analyses demonstrate that erlotinib provides a statistically …

… I study to incorporate erlotinib into two frequently used chemoradiotherapy regimens (SWOG9504
18 and CALGB39801 5 ) for unresectable Stage III NSCLC. Erlotinib, an … of erlotinib to …

… I trial established that the maximal tolerated dose of erlotinib, … No studies have been conducted
comparing a lower daily … blinded, multicenter, multinational, randomized trial comparing …

… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …

… the largest multicenter prospective clinical study of NSCLC in Taiwan. The results demonstrated
the excellent response rates, time-to-progression and overall survival of erlotinib in a …